About 22,445 results

ALLMedicine™ Ulcerative Colitis Center

Research & Reviews  7,430 results

Poor Sleep in Inflammatory Bowel Disease Is Reflective of Distinct Sleep Disorders.
https://doi.org/10.1007/s10620-021-07176-y 10.1016/j.cgh.2013.01.021 10.1097/MIB.0b013e3182a0ea54 10.1038/s41598-020-58807-9 10.1002/ibd.21580 10.5664/jcsm.26656 10.1186/s40064-016-3408-6 10.1007/s10620-013-2890-8 10.1016/j.cgh.2013.10.019 10.1111/j.1440-1746.2006.04820.x 10.1080/13548506.2020.1869796 10.1007/s00384-018-3032-8 10.1016/j.cgh.2017.12.027 10.1016/0165-1781(89)90047-4 10.1016/S1389-9457(02)00016-3 10.1001/archinte.163.2.205 10.1152/japplphysiol.00660.2005 10.1016/j.sleep.2008.10.007 10.1016/j.sleep.2014.03.025 10.1016/S1389-9457(00)00065-4 10.1093/sleep/34.5.601 10.1177/0748730415597520 10.1016/j.sleep.2018.08.002 10.1177/0748730403259849 10.1177/0748730405283154 10.5664/jcsm.26801 10.5395/rde.2013.38.1.52 10.3390/jcm9092921 10.1016/j.sleep.2011.10.033 10.1016/j.jsmc.2008.02.001 10.1007/s10620-018-5237-7 10.1093/sleep/30.2.213 10.1111/apha.13161 10.1007/s40675-018-0113-8 10.1016/j.jsmc.2015.05.004 10.1093/sleep/33.9.1159 10.1016/j.smrv.2012.09.005 10.7326/M15-2175 10.1001/archinte.164.17.1888 10.1176/appi.ajp.159.1.5 10.7326/M15-1246 10.5665/sleep.1872 10.1001/jamapsychiatry.2016.3249 10.1093/crocol/otaa052 10.3109/09540261.2014.902808 10.2147/NSS.S169312 10.1016/j.cgh.2014.02.016 10.1371/journal.pone.0156666 10.1016/j.pain.2008.01.025 10.1016/j.jpain.2013.08.007 10.1016/j.smrv.2017.08.001 10.5664/jcsm.7000
Digestive Diseases and Sciences; Salwen-Deremer JK, Smith MT et. al.

Aug 1st, 2021 - Poor sleep is common in inflammatory bowel disease (IBD), predicting increased risk of flares, surgery, and/or hospitalization and reducing quality of life. To profile specific sleep disorder symptoms in IBD, informing intervention efforts. 312 ad...

Molsidomine alleviates acetic acid-induced colitis in rats by reducing oxidative stress...
International Immunopharmacology; Mohamed NI, Suddek GM et. al.

Jul 31st, 2021 - Ulcerative colitis (UC) is a subcategory of intestinal inflammatory bowel disease characterized by up-regulation of proinflammatory cytokines and oxidative stress. The current study was designed to assess the probable protective effect of the nitr...

Comparative Efficacy for Infliximab vs. Vedolizumab in Biologic Naive Ulcerative Colitis.
Clinical Gastroenterology and Hepatology : the Official C... Narula N, Wong ECL et. al.

Jul 31st, 2021 - Comparative effectiveness studies are needed to help position therapies for ulcerative colitis (UC). We compared the efficacy of infliximab vs. vedolizumab for moderate to severe biologic-naïve UC using patient-level data from clinical trial progr...

Limonene from Agastache mexicana essential oil produces antinociceptive effects, gastro...
Journal of Ethnopharmacology; Adriana Estrella GR, María Eva GT et. al.

Jul 30th, 2021 - Agastache mexicana is a popular plant of great demand in folk medicine, essentially due to its calming properties and for alleviating arthritic, muscular and abdominal pain. Despite its spectrum for pain relief, pharmacological studies of its bioa...

see more →

Guidelines  22 results

COVID-19 Pandemic: Which IBD Patients Need to Be Scoped-Who Gets Scoped Now, Who Can Wa...
Journal of Crohn's & Colitis; Ng SC, Mak JWY et. al.

Oct 22nd, 2020 - Endoscopy is an essential component in the management of inflammatory bowel disease [IBD]. There is a risk of SARS-CoV-2 transmission during endoscopic procedures. The International Organization for the study of IBD [IOIBD] has developed 11 positi...

Pharmacological Management of Adult Outpatients With Moderate to Severely Active Ulcera...

Mar 29th, 2020 - Pharmacological Management of Adult Outpatients With Moderate to Severely Active Ulcerative Colitis: Clinical Decision Support Tool.|2020| ,|

Spotlight: Management of Moderate-to-Severe Ulcerative Colitis.
Gastroenterology Feuerstein JD, Isaacs KL et. al.

Mar 15th, 2020 - Spotlight: Management of Moderate-to-Severe Ulcerative Colitis.|2020|Feuerstein JD,Isaacs KL,Schneider Y,Siddique SM,Falck-Ytter Y,|

AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Col...
Gastroenterology Feuerstein JD, Isaacs KL et. al.

Jan 17th, 2020 - AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis.|2020|Feuerstein JD,Isaacs KL,Schneider Y,Siddique SM,Falck-Ytter Y,|therapeutic use,standards,diagnosis,immunology,therapy,diagnostic imaging,immunology,p...

Management of ulcerative colitis: summary of updated NICE guidance.
BMJ (Clinical Research Ed.); Abdulrazeg O, Li B et. al.

Oct 30th, 2019 - Management of ulcerative colitis: summary of updated NICE guidance.|2019|Abdulrazeg O,Li B,Epstein J, ,|drug therapy,methods,therapeutic use,drug therapy,drug therapy,

see more →

Drugs  380 results see all →

Clinicaltrials.gov  393 results

A Study to Investigate How Well ABBV-323 Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy

May 6th, 2020 - Study M15-722 is a Phase 2a study to investigate the efficacy and safety of ABBV-323 in participants with moderate to severe UC who failed prior therapy.

Natural History of Intestinal Inflammation in People With Primary Immune Dysregulations

May 6th, 2020 - Over 1 million people suffer from IBD in the United States. Although the exact pathogenesis is unclear, IBD results from an inappropriate inflammatory response to intestinal microbes which is influenced by the environment in a genetically suscepti...

Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.

May 5th, 2020 - This is a Phase 2a, double-blind, placebo-controlled, parallel group study in subjects with active ulcerative colitis and a non-remission (partial) response to infliximab. All enrolled subjects must have been on infliximab for a minimum of 14 week...

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

May 5th, 2020 - This study is a follow up study for subjects with Ulcerative Colitis (UC) in stable remission designed to evaluate flexible dosing of CP-690,550.

A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who...

May 1st, 2020 - The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose ...

see more →

News  728 results

New Drug Delivery System Promises More-Targeted Delivery of IBD Drugs

Jul 21st, 2021 - NEW YORK (Reuters Health) - Researchers at Progenity, Inc, in San Diego, California, are developing a new way to deliver drugs for inflammatory bowel disease (IBD) directly to the colonic mucosa, which could increase the accuracy of drug delivery ...

Upadacitinib May Help Relieve Troubling Symptoms in Ulcerative Colitis

Jul 7th, 2021 - NEW YORK (Reuters Health) - Upadacitinib, an oral selective Janus kinase (JAK)-1 inhibitor, may reduce symptoms and improves quality of life in patients with ulcerative colitis (UC), according to a post hoc analysis of data from a clinical trial. ...

Adalimumab Safe and Effective in Children With Ulcerative Colitis

Jul 6th, 2021 - NEW YORK (Reuters Health) - Adalimumab is effective and well tolerated in children with moderate-to-severe ulcerative colitis (UC), with "clinically meaningful" rates of clinical remission and response, including steroid-free remission and mucosal...

A Woman With DVT After a Flight, Anemia, and Bowel Changes

Jun 29th, 2021 - Editor's Note: The Case Challenge series includes difficult-to-diagnose conditions, some of which are not frequently encountered by most clinicians but are nonetheless important to accurately recognize. Test your diagnostic and treatment skills us...

Filgotinib 200 mg Safe, Effective for Moderate to Severe Ulcerative Colitis

Jun 15th, 2021 - (Reuters Health) - A 200-mg dose of filgotinib helped significantly more patients with ulcerative colitis than placebo to achieve clinical remission in a trial among individuals with and without prior treatment with biologics, according to a new s...

see more →

Patient Education  25 results see all →